Cellectis S.A.
OTC: CMVLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andre Choulika
- Employees
- 216
- Headquarters
- Paris, France
- IPO year
- 2014
- Market cap
- $251.9M
- Website
- https://www.cellectis.com
Loading CMVLF…
Loading profile data…Frequently asked questions about CMVLF
What does Cellectis S.A. (CMVLF) do?
Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies. Their core technology involves engineering T-cells with gene editing to express chimeric antigen receptors (CARs), enabling these modified cells to precisely target and destroy cancer cells. The company's operations are structured into two pri...
Where does CMVLF trade?
Cellectis S.A. (CMVLF) trades on the Other OTC.
What sector is CMVLF in?
Cellectis S.A. (CMVLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cellectis S.A.?
Andre Choulika is the chief executive officer of Cellectis S.A. (CMVLF).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in France.
Does CMVLF pay a dividend?
Cellectis S.A. (CMVLF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CMVLF go public?
Cellectis S.A. (CMVLF) completed its initial public offering in 2014.